Vancity Investment Management Ltd Has $9.52 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Vancity Investment Management Ltd trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.4% during the fourth quarter, HoldingsChannel reports. The fund owned 111,662 shares of the medical research company’s stock after selling 6,371 shares during the period. Edwards Lifesciences comprises about 1.3% of Vancity Investment Management Ltd’s investment portfolio, making the stock its 26th largest position. Vancity Investment Management Ltd’s holdings in Edwards Lifesciences were worth $9,519,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth about $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Finally, Dorato Capital Management acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $29,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Up 1.0%

Edwards Lifesciences stock opened at $87.51 on Friday. The stock has a 50-day simple moving average of $83.27 and a 200 day simple moving average of $83.11. The stock has a market capitalization of $50.39 billion, a P/E ratio of 46.55, a PEG ratio of 2.17 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.60.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same period last year, the firm posted $0.64 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on EW shares. BTIG Research upped their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. TD Cowen reissued a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Barclays reaffirmed an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $95.96.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the transaction, the vice president owned 40,411 shares in the company, valued at approximately $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 81,038 shares of company stock worth $6,683,255. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.